Emanuel的个人主页 - 老虎社区

Emanuel

Emanuel

暂无个人介绍

IP属地：未知

41关注

2粉丝

0主题

0勋章

2021-12-01

Longeveron

any comments ?

抱歉，原内容已删除

2021-12-01

Oh no! Any comments ?

抱歉，原内容已删除

2021-09-09

$Ree Automotive Ltd(REE)$Yeah

2021-07-22

$CFM HOLDINGS LIMITED(5EB.SI)$ Yeah ..

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3575613739783302","uuid":"3575613739783302","gmtCreate":1612526752976,"gmtModify":1637027682775,"name":"Emanuel","pinyin":"emanuel","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":41,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.36%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.80%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":603984950,"gmtCreate":1638352259192,"gmtModify":1638352259331,"author":{"id":"3575613739783302","authorId":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575613739783302","authorIdStr":"3575613739783302"},"themes":[],"htmlText":"Longeveron [What]&nbsp;any comments ?","listText":"Longeveron [What]&nbsp;any comments ?","text":"Longeveron [What] any comments ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603984950","repostId":"1121529054","repostType":2,"isVote":1,"tweetType":1,"viewCount":890,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603985630,"gmtCreate":1638352200740,"gmtModify":1638352200823,"author":{"id":"3575613739783302","authorId":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575613739783302","authorIdStr":"3575613739783302"},"themes":[],"htmlText":"Oh no! Any comments ?&nbsp;","listText":"Oh no! Any comments ?&nbsp;","text":"Oh no! Any comments ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603985630","repostId":"1121529054","repostType":2,"isVote":1,"tweetType":1,"viewCount":155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":883350409,"gmtCreate":1631205423501,"gmtModify":1631886485896,"author":{"id":"3575613739783302","authorId":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575613739783302","authorIdStr":"3575613739783302"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/REE\">$Ree Automotive Ltd(REE)$</a>Yeah&nbsp;","listText":"<a href=\"https://laohu8.com/S/REE\">$Ree Automotive Ltd(REE)$</a>Yeah&nbsp;","text":"$Ree Automotive Ltd(REE)$Yeah","images":[{"img":"https://static.tigerbbs.com/5352eef28123a9e3a4de207daac76c2e","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883350409","isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":172885943,"gmtCreate":1626951772882,"gmtModify":1631888475132,"author":{"id":"3575613739783302","authorId":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575613739783302","authorIdStr":"3575613739783302"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/5EB.SI\">$CFM HOLDINGS LIMITED(5EB.SI)$</a> Yeah ..","listText":"<a href=\"https://laohu8.com/S/5EB.SI\">$CFM HOLDINGS LIMITED(5EB.SI)$</a> Yeah ..","text":"$CFM HOLDINGS LIMITED(5EB.SI)$ Yeah ..","images":[{"img":"https://static.tigerbbs.com/d7e5749d7e13450bcbbb7200da3bb958","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172885943","isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":603984950,"gmtCreate":1638352259192,"gmtModify":1638352259331,"author":{"id":"3575613739783302","authorId":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575613739783302","authorIdStr":"3575613739783302"},"themes":[],"htmlText":"Longeveron [What]&nbsp;any comments ?","listText":"Longeveron [What]&nbsp;any comments ?","text":"Longeveron [What] any comments ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603984950","repostId":"1121529054","repostType":2,"isVote":1,"tweetType":1,"viewCount":890,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603985630,"gmtCreate":1638352200740,"gmtModify":1638352200823,"author":{"id":"3575613739783302","authorId":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575613739783302","authorIdStr":"3575613739783302"},"themes":[],"htmlText":"Oh no! Any comments ?&nbsp;","listText":"Oh no! Any comments ?&nbsp;","text":"Oh no! Any comments ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/603985630","repostId":"1121529054","repostType":2,"repost":{"id":"1121529054","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638351626,"share":"https://www.laohunote.com/m/news/1121529054?lang=&edition=full","pubTime":"2021-12-01 17:40","market":"us","language":"en","title":"Longeveron stock tumbled 20% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1121529054","media":"Tiger Newspress","summary":"Longeveron stock tumbled 20% in premarket trading after it announced pricing of a $20.5 million priv","content":"<p>Longeveron stock tumbled 20% in premarket trading&nbsp;after&nbsp;it&nbsp;announced pricing of a $20.5 million private placement.</p>\n<p><img src=\"https://static.tigerbbs.com/0985d049774f6ccfb31d70504c9d0506\" tg-width=\"851\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>Longeveron Inc.&nbsp;today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.</p>\n<p>Under the terms of the securities purchase agreement, the Company has agreed to sell approximately 1.17 million shares of its common stock and warrants to purchase 1.17 million shares of common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $17.50 per share. The warrants will expire five years from the date of issuance. The purchase price for one share of common stock and one corresponding warrant will be $17.50. The gross proceeds to the Company from the private placement are estimated to be approximately $20.5 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 3, 2021, subject to the satisfaction of customary closing conditions.</p>\n<p>Longeveron intends to use the net proceeds from the private placement to support the ongoing clinical development of Lomecel-B, the Company’s lead investigational product, which is currently being evaluated as a potential therapeutic for Hypoplastic Left Heart Syndrome, Aging Frailty Alzheimer’s Disease and other diseases. In addition, the Company plans to use the proceeds to fund additional research and development, product development, and for general and administrative purposes.</p>\n<p>EF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering.</p>\n<p><b>About Longeveron Inc.</b></p>\n<p>Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longeveron stock tumbled 20% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongeveron stock tumbled 20% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-01 17:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Longeveron stock tumbled 20% in premarket trading&nbsp;after&nbsp;it&nbsp;announced pricing of a $20.5 million private placement.</p>\n<p><img src=\"https://static.tigerbbs.com/0985d049774f6ccfb31d70504c9d0506\" tg-width=\"851\" tg-height=\"619\" referrerpolicy=\"no-referrer\"></p>\n<p>Longeveron Inc.&nbsp;today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.</p>\n<p>Under the terms of the securities purchase agreement, the Company has agreed to sell approximately 1.17 million shares of its common stock and warrants to purchase 1.17 million shares of common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $17.50 per share. The warrants will expire five years from the date of issuance. The purchase price for one share of common stock and one corresponding warrant will be $17.50. The gross proceeds to the Company from the private placement are estimated to be approximately $20.5 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 3, 2021, subject to the satisfaction of customary closing conditions.</p>\n<p>Longeveron intends to use the net proceeds from the private placement to support the ongoing clinical development of Lomecel-B, the Company’s lead investigational product, which is currently being evaluated as a potential therapeutic for Hypoplastic Left Heart Syndrome, Aging Frailty Alzheimer’s Disease and other diseases. In addition, the Company plans to use the proceeds to fund additional research and development, product development, and for general and administrative purposes.</p>\n<p>EF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering.</p>\n<p><b>About Longeveron Inc.</b></p>\n<p>Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LGVN":"Longeveron Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121529054","content_text":"Longeveron stock tumbled 20% in premarket trading after it announced pricing of a $20.5 million private placement.\n\nLongeveron Inc. today announced that it entered into a securities purchase agreement with certain institutional investors to purchase approximately $20.5 million worth of its common stock and warrants in a private placement.\nUnder the terms of the securities purchase agreement, the Company has agreed to sell approximately 1.17 million shares of its common stock and warrants to purchase 1.17 million shares of common stock. The warrants will be exercisable immediately upon the date of issuance and have an exercise price of $17.50 per share. The warrants will expire five years from the date of issuance. The purchase price for one share of common stock and one corresponding warrant will be $17.50. The gross proceeds to the Company from the private placement are estimated to be approximately $20.5 million before deducting the placement agent's fees and other estimated offering expenses. The offering is expected to close on or about December 3, 2021, subject to the satisfaction of customary closing conditions.\nLongeveron intends to use the net proceeds from the private placement to support the ongoing clinical development of Lomecel-B, the Company’s lead investigational product, which is currently being evaluated as a potential therapeutic for Hypoplastic Left Heart Syndrome, Aging Frailty Alzheimer’s Disease and other diseases. In addition, the Company plans to use the proceeds to fund additional research and development, product development, and for general and administrative purposes.\nEF Hutton, division of Benchmark Investments, LLC, is acting as exclusive placement agent for the offering.\nAbout Longeveron Inc.\nLongeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.","news_type":1},"isVote":1,"tweetType":1,"viewCount":155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":172885943,"gmtCreate":1626951772882,"gmtModify":1631888475132,"author":{"id":"3575613739783302","authorId":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575613739783302","authorIdStr":"3575613739783302"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/5EB.SI\">$CFM HOLDINGS LIMITED(5EB.SI)$</a> Yeah ..","listText":"<a href=\"https://laohu8.com/S/5EB.SI\">$CFM HOLDINGS LIMITED(5EB.SI)$</a> Yeah ..","text":"$CFM HOLDINGS LIMITED(5EB.SI)$ Yeah ..","images":[{"img":"https://static.tigerbbs.com/d7e5749d7e13450bcbbb7200da3bb958","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172885943","isVote":1,"tweetType":1,"viewCount":109,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":883350409,"gmtCreate":1631205423501,"gmtModify":1631886485896,"author":{"id":"3575613739783302","authorId":"3575613739783302","name":"Emanuel","avatar":"https://static.tigerbbs.com/3242dcd06ff1360274cd5c881f8d542e","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575613739783302","authorIdStr":"3575613739783302"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/REE\">$Ree Automotive Ltd(REE)$</a>Yeah&nbsp;","listText":"<a href=\"https://laohu8.com/S/REE\">$Ree Automotive Ltd(REE)$</a>Yeah&nbsp;","text":"$Ree Automotive Ltd(REE)$Yeah","images":[{"img":"https://static.tigerbbs.com/5352eef28123a9e3a4de207daac76c2e","width":"1170","height":"2026"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/883350409","isVote":1,"tweetType":1,"viewCount":90,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}